Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Page Path

HOME
ARTICLE CATEGORY
Review

Review

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 4051 Download: 302 Web of Science: 16 Crossref: 14

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4052 Download: 162 Web of Science: 17 Crossref: 17

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 13476 Download: 1,072 Web of Science: 64 Crossref: 80

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 4876 Download: 230 Web of Science: 12 Crossref: 14

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 3938 Download: 177 Web of Science: 9 Crossref: 12

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 5312 Download: 263 Web of Science: 15 Crossref: 18

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 4995 Download: 293 Web of Science: 20 Crossref: 20

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 5709 Download: 277 Web of Science: 8 Crossref: 9

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4023 Download: 193 Web of Science: 11 Crossref: 12

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4098 Download: 219 Web of Science: 15 Crossref: 15

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 4654 Download: 266 Web of Science: 6 Crossref: 5

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 4464 Download: 227 Web of Science: 20 Crossref: 22

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 3652 Download: 105

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 10153 Download: 432 Web of Science: 79 Crossref: 108

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 5786 Download: 312 Web of Science: 6 Crossref: 7

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3345 Download: 197 Web of Science: 8 Crossref: 11

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 3691 Download: 135 Web of Science: 5 Crossref: 5

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3284 Download: 111 Web of Science: 5 Crossref: 5

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 6799 Download: 493 Web of Science: 31 Crossref: 35

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 5673 Download: 252 Web of Science: 11 Crossref: 13

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5019 Download: 202 Web of Science: 8 Crossref: 9

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 3821 Download: 224 Web of Science: 7 Crossref: 8

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 9593 Download: 640 Web of Science: 34 Crossref: 37

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park, Young S. Hahn

Clin Mol Hepatol. 2023;29(1):65-76. Published online August 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0032

View: 5409 Download: 181 Web of Science: 8 Crossref: 11

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 5249 Download: 235 Web of Science: 15 Crossref: 14

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 6109 Download: 249 Web of Science: 10 Crossref: 11

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0104

View: 9944 Download: 874 Web of Science: 12 Crossref: 12

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 9492 Download: 175 Web of Science: 4 Crossref: 5

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 7171 Download: 492 Web of Science: 43 Crossref: 43

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 5115 Download: 249 Web of Science: 18 Crossref: 21

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 6733	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5782	MAFLD: How is it different from NAFLD?
Viewed By 5536	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4847	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4473	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 169	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 108	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 80	MAFLD: How is it different from NAFLD?
Cited By 77	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach